CLV IntelligenceReimbursement Policy Monitoring

Code intelligence

FDA-NDA207356 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code FDA-NDA207356.

Elevated code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Elevated
0

Critical

0%

1

High

100%

0

Routine

0%

0

Low

0%

New this month

—

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: ARIKAYCE (AMIKACIN) — Type 3 - New Dosage Form

Policy FDA-NDA207356 · Pulmonology

High

Arikayce (amikacin liposomal inhalation suspension) received FDA approval in September 2018 as an inhaled orphan drug for refractory Mycobacterium avium complex (MAC) lung disease, administered via a

View alert

Audit documentation

Building an audit file that includes FDA-NDA207356?

The Tripwire Audit Pack exports 12 months of Pulmonology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Pulmonology audit pack — $349One-time purchase · not a subscription